http://142-54-23-223.fusionmedialtd.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 17 Jul 2026 10:42:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://142-54-23-223.fusionmedialtd.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Compass+Therapeutics+Announces+Tovecimig+Data+Accepted+for+an+Oral+Presentation+at+the+ESMO+Congress+2026/26782861.html <p align="left">BOSTON, July 17, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that its abstract titled “A randomized trial of paclitaxel ± tovecimig in previously treated patients with advanced biliary tract cancer” has been accepted for an oral Proffered Paper presentation at the upcoming European Society for Medical Oncology (ESMO) Congress. The congress will take place October 23-27, 2026 in Madrid, Spain.</p> <p align="left">The presentation will highlight the results of the randomized, controlled Phase 2/3 COMPANION-002 clinical trial assessing tovecimig http://www.streetinsider.com/Press+Releases/Compass+Therapeutics+Announces+Tovecimig+Data+Accepted+for+an+Oral+Presentation+at+the+ESMO+Congress+2026/26782861.html Fri, 17 Jul 2026 10:42:00 -0400 A.08435063 CMPX O.20032280 O.49925668 http://www.streetinsider.com/Press+Releases/Compass+Therapeutics+Announces+Tovecimig+Data+Accepted+for+an+Oral+Presentation+at+the+ESMO+Congress+2026/26782861.html <p align="left">BOSTON, July 17, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that its abstract titled “A randomized trial of paclitaxel ± tovecimig in previously treated patients with advanced biliary tract cancer” has been accepted for an oral Proffered Paper presentation at the upcoming European Society for Medical Oncology (ESMO) Congress. The congress will take place October 23-27, 2026 in Madrid, Spain.</p> <p align="left">The presentation will highlight the results of the randomized, controlled Phase 2/3 COMPANION-002 clinical trial assessing tovecimig http://www.streetinsider.com/Press+Releases/Compass+Therapeutics+Announces+Tovecimig+Data+Accepted+for+an+Oral+Presentation+at+the+ESMO+Congress+2026/26782861.html Fri, 17 Jul 2026 10:42:00 -0400 A.08435063 CMPX O.20032280 O.49925668 http://www.streetinsider.com/Press+Releases/Compass+Therapeutics+Announces+Tovecimig+Data+Accepted+for+an+Oral+Presentation+at+the+ESMO+Congress+2026/26782861.html <p align="left">BOSTON, July 17, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that its abstract titled “A randomized trial of paclitaxel ± tovecimig in previously treated patients with advanced biliary tract cancer” has been accepted for an oral Proffered Paper presentation at the upcoming European Society for Medical Oncology (ESMO) Congress. The congress will take place October 23-27, 2026 in Madrid, Spain.</p> <p align="left">The presentation will highlight the results of the randomized, controlled Phase 2/3 COMPANION-002 clinical trial assessing tovecimig http://www.streetinsider.com/Press+Releases/Compass+Therapeutics+Announces+Tovecimig+Data+Accepted+for+an+Oral+Presentation+at+the+ESMO+Congress+2026/26782861.html Fri, 17 Jul 2026 10:42:00 -0400 A.08435063 CMPX O.20032280 O.49925668 http://www.streetinsider.com/Press+Releases/Compass+Therapeutics+Announces+Tovecimig+Data+Accepted+for+an+Oral+Presentation+at+the+ESMO+Congress+2026/26782861.html <p align="left">BOSTON, July 17, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that its abstract titled “A randomized trial of paclitaxel ± tovecimig in previously treated patients with advanced biliary tract cancer” has been accepted for an oral Proffered Paper presentation at the upcoming European Society for Medical Oncology (ESMO) Congress. The congress will take place October 23-27, 2026 in Madrid, Spain.</p> <p align="left">The presentation will highlight the results of the randomized, controlled Phase 2/3 COMPANION-002 clinical trial assessing tovecimig http://www.streetinsider.com/Press+Releases/Compass+Therapeutics+Announces+Tovecimig+Data+Accepted+for+an+Oral+Presentation+at+the+ESMO+Congress+2026/26782861.html Fri, 17 Jul 2026 10:42:00 -0400 A.08435063 CMPX O.20032280 O.49925668 http://www.streetinsider.com/Globe+Newswire/Compass+Therapeutics+Announces+Tovecimig+Data+Accepted+for+an+Oral+Presentation+at+the+ESMO+Congress+2026/26782861.html <p align="left">BOSTON, July 17, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that its abstract titled “A randomized trial of paclitaxel ± tovecimig in previously treated patients with advanced biliary tract cancer” has been accepted for an oral Proffered Paper presentation at the upcoming European Society for Medical Oncology (ESMO) Congress. The congress will take place October 23-27, 2026 in Madrid, Spain.</p> <p align="left">The presentation will highlight the results of the randomized, controlled Phase 2/3 COMPANION-002 clinical trial assessing tovecimig http://www.streetinsider.com/Globe+Newswire/Compass+Therapeutics+Announces+Tovecimig+Data+Accepted+for+an+Oral+Presentation+at+the+ESMO+Congress+2026/26782861.html Fri, 17 Jul 2026 10:42:00 -0400 A.08435063 CMPX O.20032280 O.49925668 http://www.streetinsider.com/Globe+Newswire/Compass+Therapeutics+Announces+Tovecimig+Data+Accepted+for+an+Oral+Presentation+at+the+ESMO+Congress+2026/26782861.html <p align="left">BOSTON, July 17, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that its abstract titled “A randomized trial of paclitaxel ± tovecimig in previously treated patients with advanced biliary tract cancer” has been accepted for an oral Proffered Paper presentation at the upcoming European Society for Medical Oncology (ESMO) Congress. The congress will take place October 23-27, 2026 in Madrid, Spain.</p> <p align="left">The presentation will highlight the results of the randomized, controlled Phase 2/3 COMPANION-002 clinical trial assessing tovecimig http://www.streetinsider.com/Globe+Newswire/Compass+Therapeutics+Announces+Tovecimig+Data+Accepted+for+an+Oral+Presentation+at+the+ESMO+Congress+2026/26782861.html Fri, 17 Jul 2026 10:42:00 -0400 A.08435063 CMPX O.20032280 O.49925668 http://www.streetinsider.com/Globe+Newswire/Compass+Therapeutics+Announces+Tovecimig+Data+Accepted+for+an+Oral+Presentation+at+the+ESMO+Congress+2026/26782861.html <p align="left">BOSTON, July 17, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that its abstract titled “A randomized trial of paclitaxel ± tovecimig in previously treated patients with advanced biliary tract cancer” has been accepted for an oral Proffered Paper presentation at the upcoming European Society for Medical Oncology (ESMO) Congress. The congress will take place October 23-27, 2026 in Madrid, Spain.</p> <p align="left">The presentation will highlight the results of the randomized, controlled Phase 2/3 COMPANION-002 clinical trial assessing tovecimig http://www.streetinsider.com/Globe+Newswire/Compass+Therapeutics+Announces+Tovecimig+Data+Accepted+for+an+Oral+Presentation+at+the+ESMO+Congress+2026/26782861.html Fri, 17 Jul 2026 10:42:00 -0400 A.08435063 CMPX O.20032280 O.49925668 http://www.streetinsider.com/Globe+Newswire/Compass+Therapeutics+Announces+Tovecimig+Data+Accepted+for+an+Oral+Presentation+at+the+ESMO+Congress+2026/26782861.html <p align="left">BOSTON, July 17, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that its abstract titled “A randomized trial of paclitaxel ± tovecimig in previously treated patients with advanced biliary tract cancer” has been accepted for an oral Proffered Paper presentation at the upcoming European Society for Medical Oncology (ESMO) Congress. The congress will take place October 23-27, 2026 in Madrid, Spain.</p> <p align="left">The presentation will highlight the results of the randomized, controlled Phase 2/3 COMPANION-002 clinical trial assessing tovecimig http://www.streetinsider.com/Globe+Newswire/Compass+Therapeutics+Announces+Tovecimig+Data+Accepted+for+an+Oral+Presentation+at+the+ESMO+Congress+2026/26782861.html Fri, 17 Jul 2026 10:42:00 -0400 A.08435063 CMPX O.20032280 O.49925668 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Compass+Therapeutics%2C+++++For%3A+Jul+01/26721868.html si-local-file:///var/storage/secattach/20260701/26721868.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Compass+Therapeutics%2C+++++For%3A+Jul+01/26721868.html Wed, 01 Jul 2026 17:01:00 -0400 CMPX O.49925668 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Compass+Therapeutics%2C+++++For%3A+Jul+01/26721868.html si-local-file:///var/storage/secattach/20260701/26721868.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Compass+Therapeutics%2C+++++For%3A+Jul+01/26721868.html Wed, 01 Jul 2026 17:01:00 -0400 CMPX O.49925668 http://www.streetinsider.com/New+Coverage/Ladenburg+Thalmann+Assumes+Compass+Therapeutics+%28CMPX%29+at+Buy/26716453.html <p>Ladenburg Thalmann analyst Kevin DeGeeter assumes coverage on Compass Therapeutics (NASDAQ: CMPX) with a Buy rating and a price target of $5.00.</p><p>For an analyst ratings summary and ratings history on Compass Therapeutics <a href="http://www.streetinsider.com/rating_history.php?q=CMPX">click here</a>. For more ratings news on Compass Therapeutics <a href="http://www.streetinsider.com/stock_lookup_news.php?q=CMPX&amp;type=analyst">click here</a>.</p><p>Shares of Compass Therapeutics closed at $2.19 yesterday.</p> http://www.streetinsider.com/New+Coverage/Ladenburg+Thalmann+Assumes+Compass+Therapeutics+%28CMPX%29+at+Buy/26716453.html Wed, 01 Jul 2026 06:35:03 -0400 CMPX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Compass+Therapeutics%2C+++++For%3A+Jun+22/26675193.html si-local-file:///var/storage/secattach/20260623/26675193.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Compass+Therapeutics%2C+++++For%3A+Jun+22/26675193.html Tue, 23 Jun 2026 06:00:00 -0400 CMPX O.49925668 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Compass+Therapeutics%2C+++++For%3A+Jun+22/26675193.html si-local-file:///var/storage/secattach/20260623/26675193.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Compass+Therapeutics%2C+++++For%3A+Jun+22/26675193.html Tue, 23 Jun 2026 06:00:00 -0400 CMPX O.49925668 http://www.streetinsider.com/Press+Releases/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html <p align="left"><em>Issued on behalf of GT Biopharma, Inc.</em></p> <p align="left"><em>Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for cancers that have resisted everything else.</em></p> <p align="left">SAN FRANCISCO, June 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=hqf29VbrX-9-C6m0V_cBNDnlGi6-4EsKJBh9s-pfYkgKAaNL-Sl-aDcqy-saXEknyLtkiiZlV89PSyldUHVuRMeUUNE3qN9JlScOHrJUg7w=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — The last decade of cancer immunotherapy was written largely in the language of T cells. Checkpoint inhibitors unleashed them; CAR-T therapies re-engineered them and produced some of the most dramatic remissions modern medicine has ever recorded. http://www.streetinsider.com/Press+Releases/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html Fri, 12 Jun 2026 08:10:00 -0400 CMPX CRBU FATE GTBP NKTX http://www.streetinsider.com/Press+Releases/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html <p align="left"><em>Issued on behalf of GT Biopharma, Inc.</em></p> <p align="left"><em>Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for cancers that have resisted everything else.</em></p> <p align="left">SAN FRANCISCO, June 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=hqf29VbrX-9-C6m0V_cBNDnlGi6-4EsKJBh9s-pfYkgKAaNL-Sl-aDcqy-saXEknyLtkiiZlV89PSyldUHVuRMeUUNE3qN9JlScOHrJUg7w=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — The last decade of cancer immunotherapy was written largely in the language of T cells. Checkpoint inhibitors unleashed them; CAR-T therapies re-engineered them and produced some of the most dramatic remissions modern medicine has ever recorded. http://www.streetinsider.com/Press+Releases/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html Fri, 12 Jun 2026 08:10:00 -0400 CMPX CRBU FATE GTBP NKTX http://www.streetinsider.com/Press+Releases/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html <p align="left"><em>Issued on behalf of GT Biopharma, Inc.</em></p> <p align="left"><em>Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for cancers that have resisted everything else.</em></p> <p align="left">SAN FRANCISCO, June 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=hqf29VbrX-9-C6m0V_cBNDnlGi6-4EsKJBh9s-pfYkgKAaNL-Sl-aDcqy-saXEknyLtkiiZlV89PSyldUHVuRMeUUNE3qN9JlScOHrJUg7w=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — The last decade of cancer immunotherapy was written largely in the language of T cells. Checkpoint inhibitors unleashed them; CAR-T therapies re-engineered them and produced some of the most dramatic remissions modern medicine has ever recorded. http://www.streetinsider.com/Press+Releases/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html Fri, 12 Jun 2026 08:10:00 -0400 CMPX CRBU FATE GTBP NKTX http://www.streetinsider.com/Press+Releases/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html <p align="left"><em>Issued on behalf of GT Biopharma, Inc.</em></p> <p align="left"><em>Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for cancers that have resisted everything else.</em></p> <p align="left">SAN FRANCISCO, June 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=hqf29VbrX-9-C6m0V_cBNDnlGi6-4EsKJBh9s-pfYkgKAaNL-Sl-aDcqy-saXEknyLtkiiZlV89PSyldUHVuRMeUUNE3qN9JlScOHrJUg7w=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — The last decade of cancer immunotherapy was written largely in the language of T cells. Checkpoint inhibitors unleashed them; CAR-T therapies re-engineered them and produced some of the most dramatic remissions modern medicine has ever recorded. http://www.streetinsider.com/Press+Releases/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html Fri, 12 Jun 2026 08:10:00 -0400 CMPX CRBU FATE GTBP NKTX http://www.streetinsider.com/Press+Releases/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html <p align="left"><em>Issued on behalf of GT Biopharma, Inc.</em></p> <p align="left"><em>Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for cancers that have resisted everything else.</em></p> <p align="left">SAN FRANCISCO, June 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=hqf29VbrX-9-C6m0V_cBNDnlGi6-4EsKJBh9s-pfYkgKAaNL-Sl-aDcqy-saXEknyLtkiiZlV89PSyldUHVuRMeUUNE3qN9JlScOHrJUg7w=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — The last decade of cancer immunotherapy was written largely in the language of T cells. Checkpoint inhibitors unleashed them; CAR-T therapies re-engineered them and produced some of the most dramatic remissions modern medicine has ever recorded. http://www.streetinsider.com/Press+Releases/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html Fri, 12 Jun 2026 08:10:00 -0400 CMPX CRBU FATE GTBP NKTX http://www.streetinsider.com/Globe+Newswire/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html <p align="left"><em>Issued on behalf of GT Biopharma, Inc.</em></p> <p align="left"><em>Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for cancers that have resisted everything else.</em></p> <p align="left">SAN FRANCISCO, June 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=hqf29VbrX-9-C6m0V_cBNDnlGi6-4EsKJBh9s-pfYkgKAaNL-Sl-aDcqy-saXEknyLtkiiZlV89PSyldUHVuRMeUUNE3qN9JlScOHrJUg7w=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — The last decade of cancer immunotherapy was written largely in the language of T cells. Checkpoint inhibitors unleashed them; CAR-T therapies re-engineered them and produced some of the most dramatic remissions modern medicine has ever recorded. http://www.streetinsider.com/Globe+Newswire/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html Fri, 12 Jun 2026 08:10:00 -0400 CMPX CRBU FATE GTBP NKTX http://www.streetinsider.com/Globe+Newswire/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html <p align="left"><em>Issued on behalf of GT Biopharma, Inc.</em></p> <p align="left"><em>Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for cancers that have resisted everything else.</em></p> <p align="left">SAN FRANCISCO, June 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=hqf29VbrX-9-C6m0V_cBNDnlGi6-4EsKJBh9s-pfYkgKAaNL-Sl-aDcqy-saXEknyLtkiiZlV89PSyldUHVuRMeUUNE3qN9JlScOHrJUg7w=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — The last decade of cancer immunotherapy was written largely in the language of T cells. Checkpoint inhibitors unleashed them; CAR-T therapies re-engineered them and produced some of the most dramatic remissions modern medicine has ever recorded. http://www.streetinsider.com/Globe+Newswire/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html Fri, 12 Jun 2026 08:10:00 -0400 CMPX CRBU FATE GTBP NKTX http://www.streetinsider.com/Globe+Newswire/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html <p align="left"><em>Issued on behalf of GT Biopharma, Inc.</em></p> <p align="left"><em>Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for cancers that have resisted everything else.</em></p> <p align="left">SAN FRANCISCO, June 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=hqf29VbrX-9-C6m0V_cBNDnlGi6-4EsKJBh9s-pfYkgKAaNL-Sl-aDcqy-saXEknyLtkiiZlV89PSyldUHVuRMeUUNE3qN9JlScOHrJUg7w=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — The last decade of cancer immunotherapy was written largely in the language of T cells. Checkpoint inhibitors unleashed them; CAR-T therapies re-engineered them and produced some of the most dramatic remissions modern medicine has ever recorded. http://www.streetinsider.com/Globe+Newswire/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html Fri, 12 Jun 2026 08:10:00 -0400 CMPX CRBU FATE GTBP NKTX http://www.streetinsider.com/Globe+Newswire/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html <p align="left"><em>Issued on behalf of GT Biopharma, Inc.</em></p> <p align="left"><em>Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for cancers that have resisted everything else.</em></p> <p align="left">SAN FRANCISCO, June 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=hqf29VbrX-9-C6m0V_cBNDnlGi6-4EsKJBh9s-pfYkgKAaNL-Sl-aDcqy-saXEknyLtkiiZlV89PSyldUHVuRMeUUNE3qN9JlScOHrJUg7w=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — The last decade of cancer immunotherapy was written largely in the language of T cells. Checkpoint inhibitors unleashed them; CAR-T therapies re-engineered them and produced some of the most dramatic remissions modern medicine has ever recorded. http://www.streetinsider.com/Globe+Newswire/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html Fri, 12 Jun 2026 08:10:00 -0400 CMPX CRBU FATE GTBP NKTX http://www.streetinsider.com/Globe+Newswire/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html <p align="left"><em>Issued on behalf of GT Biopharma, Inc.</em></p> <p align="left"><em>Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for cancers that have resisted everything else.</em></p> <p align="left">SAN FRANCISCO, June 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=hqf29VbrX-9-C6m0V_cBNDnlGi6-4EsKJBh9s-pfYkgKAaNL-Sl-aDcqy-saXEknyLtkiiZlV89PSyldUHVuRMeUUNE3qN9JlScOHrJUg7w=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — The last decade of cancer immunotherapy was written largely in the language of T cells. Checkpoint inhibitors unleashed them; CAR-T therapies re-engineered them and produced some of the most dramatic remissions modern medicine has ever recorded. http://www.streetinsider.com/Globe+Newswire/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html Fri, 12 Jun 2026 08:10:00 -0400 CMPX CRBU FATE GTBP NKTX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Compass+Therapeutics%2C+++++For%3A+Jun+10/26635492.html si-local-file:///var/storage/secattach/20260611/26635492.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Compass+Therapeutics%2C+++++For%3A+Jun+10/26635492.html Thu, 11 Jun 2026 16:01:00 -0400 CMPX O.49925668 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Compass+Therapeutics%2C+++++For%3A+Jun+10/26635492.html si-local-file:///var/storage/secattach/20260611/26635492.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Compass+Therapeutics%2C+++++For%3A+Jun+10/26635492.html Thu, 11 Jun 2026 16:01:00 -0400 CMPX O.49925668